share_log

Cybin | 6-K: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K:外國發行人報告(業績相關)
美股SEC公告 ·  08/09 01:44

Moomoo AI 已提取核心訊息

Cybin Inc., a clinical-stage neuropsychiatric company, filed its unaudited condensed interim consolidated financial statements for the three months ended June 30, 2024, with the United States Securities and Exchange Commission. The report, dated August 8, 2024, indicates a net loss of $14,824,000 for the period, compared to a net loss of $14,514,000 for the same period in 2023. The company's total assets decreased to $284,647,000 from $302,023,000 as of March 31, 2024. The total shareholders' equity also saw a decline to $279,832,000 from $291,927,000. The financial statements were prepared in accordance with International Accounting Standards and should be read in conjunction with Cybin’s annual financial statements. The company's cash position decreased from $208,992,000 to $183,275,000. Cybin Inc. is focused on advancing therapies and delivery mechanisms for psychiatric and neurological conditions and is developing proprietary molecules and delivery systems to be studied through clinical trials.
Cybin Inc., a clinical-stage neuropsychiatric company, filed its unaudited condensed interim consolidated financial statements for the three months ended June 30, 2024, with the United States Securities and Exchange Commission. The report, dated August 8, 2024, indicates a net loss of $14,824,000 for the period, compared to a net loss of $14,514,000 for the same period in 2023. The company's total assets decreased to $284,647,000 from $302,023,000 as of March 31, 2024. The total shareholders' equity also saw a decline to $279,832,000 from $291,927,000. The financial statements were prepared in accordance with International Accounting Standards and should be read in conjunction with Cybin’s annual financial statements. The company's cash position decreased from $208,992,000 to $183,275,000. Cybin Inc. is focused on advancing therapies and delivery mechanisms for psychiatric and neurological conditions and is developing proprietary molecules and delivery systems to be studied through clinical trials.
世賓醫療公司是一家臨床階段神經精神科公司,已向美國證券交易所提交了截至2024年6月30日的未經審計的簡明中期合併財務報表。報告日期爲2024年8月8日,期內淨虧損爲14,824,000美元,與2023年同期的淨虧損14,514,000美元相比略有增加。該公司的總資產從2024年3月31日的302,023,000美元下降到284,647,000美元。股東權益總額也從291,927,000美元下降到279,832,000美元。該財務報表是按照國際會計準則編制的,應與世賓的年度財務報表一起閱讀。該公司的現金餘額由208,992,000美元降至183,275,000美元。世賓公司專注於推進精神和神經疾病的治療和傳遞機制,並開發專有分子和傳遞系統通過臨床試驗研究。
世賓醫療公司是一家臨床階段神經精神科公司,已向美國證券交易所提交了截至2024年6月30日的未經審計的簡明中期合併財務報表。報告日期爲2024年8月8日,期內淨虧損爲14,824,000美元,與2023年同期的淨虧損14,514,000美元相比略有增加。該公司的總資產從2024年3月31日的302,023,000美元下降到284,647,000美元。股東權益總額也從291,927,000美元下降到279,832,000美元。該財務報表是按照國際會計準則編制的,應與世賓的年度財務報表一起閱讀。該公司的現金餘額由208,992,000美元降至183,275,000美元。世賓公司專注於推進精神和神經疾病的治療和傳遞機制,並開發專有分子和傳遞系統通過臨床試驗研究。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息